Guidelines for computer modeling of diabetes and its complications.
about
Development of an economic evaluation of diagnostic strategies: the case of monogenic diabetesMechanistic systems modeling to guide drug discovery and developmentTemporal validation of the UKPDS outcomes model using 10-year posttrial monitoring dataTowards renewed health economic simulation of type 2 diabetes: risk equations for first and second cardiovascular events from Swedish register data.UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82.Predicting mortality in people with type 2 diabetes mellitus after major complications: a study using Swedish National Diabetes Register data.A critical review of mathematical models and data used in diabetology.Indirect estimation of a discrete-state discrete-time model using secondary data analysis of regression data.Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA.Current challenges in health economic modeling of cancer therapies: a research inquiry.Cost-effectiveness of aspirin use among persons with newly diagnosed type 2 diabetes.Health economic evaluations comparing insulin glargine with NPH insulin in patients with type 1 diabetes: a systematic review.Age-corrected beta cell mass following onset of type 1 diabetes mellitus correlates with plasma C-peptide in humansChronic disease modeling and simulation software.The Relative Effectiveness of Pumps Over MDI and Structured Education (REPOSE): study protocol for a cluster randomised controlled trialStudy protocol: a multi-professional team intervention of physical activity referrals in primary care patients with cardiovascular risk factors--the Dalby lifestyle intervention cohort (DALICO) study.Validation of the IHE Cohort Model of Type 2 Diabetes and the impact of choice of macrovascular risk equationsHealth-related quality of life in diabetic people with different vascular risk.Estimated incidence of cardiovascular complications related to type 2 diabetes in Mexico using the UKPDS outcome model and a population-based survey.Medical costs associated with type 2 diabetes complications and comorbidities.Age, gender, insulin and blood glucose control status alter the risk of ischemic heart disease and stroke among elderly diabetic patientsDynamic microsimulation models for health outcomes: a reviewCost-effectiveness of oral hypoglycaemic agents for the treatment of type 2 diabetes mellitus.Drug-induced metabolic syndrome.Crossing the evidence chasm: building evidence bridges from process changes to clinical outcomesA model qualification method for mechanistic physiological QSP models to support model-informed drug development.Metabolic predictors of ischemic heart disease and cerebrovascular attack in elderly diabetic individuals: difference in risk by age.The impact of prevention on reducing the burden of cardiovascular diseaseRelationship of insulin resistance and related metabolic variables to coronary artery disease: a mathematical analysisLong-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.Low HDL cholesterol is associated with the risk of stroke in elderly diabetic individuals: changes in the risk for atherosclerotic diseases at various agesElevated triglycerides correlate with progression of diabetic neuropathyLiraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in SpainCan modeling of health outcomes facilitate regulatory decision making? The benefit-risk tradeoff for rosiglitazone in 1999 vs. 2007.Projected long-term outcomes in patients with type 1 diabetes treated with fast-acting insulin aspart vs conventional insulin aspart in the UK setting.IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting.Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting.Modeling the Long-Term Cost-Effectiveness of IDegLira in Patients with Type 2 Diabetes Who are Failing To Meet Glycemic Targets on Basal Insulin Alone in The Netherlands.Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA.Simulating lifetime outcomes associated with complications for people with type 1 diabetes.
P2860
Q28689671-F5EF53B9-5D67-4DDE-BE0A-AFCF737F85FCQ30414988-0033B68A-36A3-4AFC-9030-41E772AF6869Q30583586-775074D8-9037-4D37-86FC-1A50D4ED195CQ30625765-E5A44023-4FB5-436A-A83E-BB2570E969AAQ30651159-22D15AD8-3889-41D0-8CE6-D8C26EAAB6CBQ30805323-E6F2CAB6-1619-4263-8167-79B8692A5034Q31047512-F6011559-E34E-470C-AA25-8AF39388A453Q33448660-6636E926-5F18-4FB7-B446-5E05EE4122B4Q33700904-2F8592CF-5935-4DFA-A817-E9D761368B6FQ33805471-B5C82F84-BCB4-4CFE-BFA8-F993638A93DFQ33873025-90E2F557-22B9-47A9-8649-79E97FD832BBQ34042148-CA8E9F91-CE47-4049-94E8-CD574269C404Q34071649-35259B18-50E2-4B20-AED1-3C334CE14F01Q34108081-802941FE-4F94-4640-979B-3738F6D82B9BQ34151785-B9D3AA0E-AA38-4F98-AE51-E778ED3C3B9FQ34315071-85E9DEA2-5689-4C58-B143-570CED5FCBF0Q34332236-EDA664DE-1DA9-4B31-8CFF-567EC4DE519EQ34418579-ADD7D698-6F81-4312-BA5F-06275D41FA06Q34503859-2C79C754-36F0-4059-A0F7-CC69AE0F09C5Q35110549-C3932044-DC33-4BFE-B980-23618339E0CFQ35431762-1CF637C9-A2E8-4C14-8DC1-65D3A79CBBC5Q36116257-42C5E3D8-200E-406F-98A1-52679F2E58FDQ36150707-13E970AB-B94A-4385-8D18-815DE3B6D1DDQ36392681-1A6E6D44-A49E-49AE-B095-0F14E3737951Q36463135-6CE1DF0B-2D54-49A7-9AD8-C7577D8B9A61Q36600060-68E1F9F9-77D7-4EDF-BB03-E2272917FD3AQ36687937-C8B5C99A-C176-4078-88A9-7487B7C0A16FQ36807520-72D6A8F3-11B1-450A-89A2-F81091B7AB59Q37067169-66D8ABA4-6BA4-46AE-AD02-16A83848FCDFQ37154802-15470831-0751-4060-AA80-E039C392C2A5Q37235914-16825844-1C52-4467-838F-6DF506FC878BQ37236277-01687888-7EBD-4729-B43E-E9F5B46AAE18Q37737468-CBCF36AF-73CC-4A21-81B2-F4A87911D5C1Q37834962-F583A97C-B0A9-4464-8B83-C5E0C3A295D9Q38675810-12CEFFC2-B506-4C18-8B25-DDA0E900B20EQ38738725-E9BA417C-6591-46E3-84E6-52F3FD55BF39Q38765656-9BBA7478-A449-4DBD-911D-C92580921697Q38775589-84C0E8B5-752F-44CB-AADD-ABAFCEAFE93AQ38907289-C2160C90-5859-4C42-A1E9-3D1FF5681B02Q39435430-50419786-E8E2-4187-9F14-D299413B5CDD
P2860
Guidelines for computer modeling of diabetes and its complications.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Guidelines for computer modeling of diabetes and its complications.
@ast
Guidelines for computer modeling of diabetes and its complications.
@en
type
label
Guidelines for computer modeling of diabetes and its complications.
@ast
Guidelines for computer modeling of diabetes and its complications.
@en
prefLabel
Guidelines for computer modeling of diabetes and its complications.
@ast
Guidelines for computer modeling of diabetes and its complications.
@en
P1433
P1476
Guidelines for computer modeling of diabetes and its complications.
@en
P2093
American Diabetes Association Consensus Panel
P304
P356
10.2337/DIACARE.27.9.2262
P407
P577
2004-09-01T00:00:00Z